OncoHub.ai
An abstract digest clustered by cancer type and ranked by clinical priority. Numerical results (HR, PFS, OS) are preserved; reliability caveats are embedded within each study's card.
Indication: 1L locally recurrent inoperable/metastatic TNBC (immunotherapy not an option)
Key finding: Primary OS HR 0.79 (P=0.0291) and PFS HR 0.57 (P<0.0001); median PFS2 15.6 vs 11.8 mo (HR 0.61, 95% CI 0.50–0.74); TFST 10.9 vs 5.6 mo (HR 0.49); TSST 16.7 vs 12.6 mo (HR 0.67).
Clinical relevance: Supports Dato-DXd as a new 1L standard of care in this setting.
Source: ASCO Abstract 1002
Indication: 1L metastatic TNBC (not PD-(L)1 candidates)
Key finding: Median PFS2 18.2 vs 14.0 mo; stratified HR 0.70 (95% CI 0.55–0.90; nominal P=0.0051); 12-mo PFS2 71% vs 59%; 18-mo 52% vs 41%; benefit despite 82% chemo-arm crossover to SG.
Clinical relevance: Confirms the 1L SG benefit extends beyond PFS1.
Source: ASCO Abstract 1001
Indication: HER2+ metastatic breast cancer (maintenance)
Key finding: Overall PFS HR 0.641 (P<0.0001); median PFS 24.9 vs 16.3 mo; cORR 22.6% vs 15.2%; consistent across de novo (28.9 vs 16.8), recurrent (21.3 vs 12.7), HR+ (25.0 vs 18.1), HR− (24.9 vs 12.6), BM+ (8.5 vs 4.2), BM− (27.2 vs 18.1 mo).
Clinical relevance: Supports TUC + HP across HER2+ MBC maintenance subgroups including brain metastases.
Source: ASCO Abstract 1005
Indication: Bone-metastatic breast cancer and CRPC
Key finding: Q12W (after 4 loading Q4W doses) non-inferior to Q4W for time to first SSE (stratified HR 1.023; 90% CI 0.874–1.197); first and subsequent SSE HR 1.043 (0.907–1.198); lower hypocalcemia (30% vs 46%) and ONJ (6.9% vs 8.5%).
Clinical relevance: Q12W denosumab is non-inferior with a favorable safety profile and reduced burden.
Source: ASCO Abstract 1004
Indication: PD-L1+ 1L metastatic TNBC
Key finding: PFS2 outcomes; full text was gated to 08:00 AM ET, 02 Jun, and was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA1000
Indication: Advanced HR+/HER2− breast cancer with emergent ESR1 mutation
Key finding: Camizestrant on emergent ESR1m; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA1007
Indication: 1L ER+/HER2− LA/mBC (persevERA) · HR+/HER2−/PIK3CA-mutant ABC (VIKTORIA-1)
Key finding: Giredestrant + palbociclib vs letrozole + palbociclib (persevERA), and gedatolisib + fulvestrant ± palbociclib (VIKTORIA-1); full text was not available in the source for either.
Clinical relevance: Unclear; must be verified against the full texts.
Source: ASCO Abstract LBA1006 / LBA1008
Indication: Locally advanced/metastatic TNBC
Key finding: Iza-bren vs chemotherapy; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA1003
Indication: R/R T-ALL/LBL and PTCL
Key finding: 18 infused; RP2D 2.0 ×10⁶/kg; ORR 77.8% (14/18); CR/CRi/CMR 61.1%; at RP2D ORR 100% with CR/CMR 85.7% (6/7); no DLTs; no grade ≥3 CRS; ICANS 5.5% (grade 1).
Clinical relevance: First clinical data of a dual-epitope CD5 CAR-T in T-cell malignancies; supports Phase 2.
Source: ASCO Abstract 6508
Indication: NPM1mt/KMT2Ar/NUP98r AML
Key finding: 1-yr OS 89%, 2-yr OS 89%, 1-yr CIR 11% (vs historical 2-yr OS 51%, 1-yr CIR 39%); thrombocytopenia common (86%, G≥3 43%).
Clinical relevance: Supports prospective evaluation of menin-inhibitor maintenance.
Source: ASCO Abstract 6505
Indication: Newly diagnosed IDH1-mutant AML
Key finding: ORR 95% (38/40); CRc 93% (37/40); MRD-negative 92% (34/37); 3-yr OS 79% (64–96%); 45% bridged to allo-SCT.
Clinical relevance: The triplet is feasible and active, with safety comparable to doublets.
Source: ASCO Abstract 6503
Indication: FLT3-ITD AML (frontline unfit + R/R)
Key finding: Frontline CR 72%, CRi 17%, MLFS 2%; EOC1 MRD-negative by MFC 58%; median RFS 24.7 mo, OS 36.5 mo; R/R CR/CRi 28%, median OS 6.3 mo.
Clinical relevance: Strong activity in older FLT3-ITD AML; supports continued development.
Source: ASCO Abstract 6504
Indication: Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Key finding: Newly diagnosed ORR 93% (all CR/CRi); median OS 15 mo; 24-mo OS 42%; 9/14 ND went to SCT; R/R ORR 100%, CR/CRi 50%; 2 grade 3 capillary leak.
Clinical relevance: Frontline use enables SCT consolidation with no early mortality.
Source: ASCO Abstract 6502
Indication: Treatment-naïve AML/MDS
Key finding: TN AML cCR 85.7% (30/35), 86.7% MRD-negative among cCR; TN MDS ORR 100% (IWG 2006), cCR 70% (IWG 2023); no DLT/TLS.
Clinical relevance: A novel selective BCL-2 inhibitor with activity also in MDS.
Source: ASCO Abstract 6506
Indication: Myelofibrosis with anemia
Key finding: 47 enrolled; 50% of non-transfusion-dependent achieved Hgb increase ≥1.5 g/dL ≥12 wks; 71% of TD-low achieved transfusion independence ≥16 wks; 67% of TD-high had ≥50% transfusion-burden reduction.
Clinical relevance: Supports hepcidin reduction as a therapeutic strategy; activity preserved with concomitant JAKi.
Source: ASCO Abstract 6501
Indication: R/R AML or HR-MDS
Key finding: 15 patients; ~90% AKT phosphorylation reduction at 60 mg; 1 CR at 45 mg; anti-leukemic activity in 4/10 cycle-1 completers; no DLTs.
Clinical relevance: First clinical validation of PI3Kγ as a target in AML/MDS; combinations planned.
Source: ASCO Abstract 6507
Indication: Adult NF1 with symptomatic inoperable plexiform neurofibromas
Key finding: Confirmed ORR by BIRC 43.8% (95% CI 34.4–53.4) vs 10.9% placebo (P<0.0001); median DoR 15.1 mo; 81.0% vs 53.6% achieved ≥2-point pain reduction.
Clinical relevance: A potential new standard of care for adult inoperable NF1 plexiform neurofibromas.
Source: ASCO Abstract 3017
Indication: JAKi-naïve myelofibrosis
Key finding: Selinexor + ruxolitinib; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA6500
Indication: 1L RAS-mutant mCRC
Key finding: Onvansertib 30 mg + FOLFIRI + bevacizumab ORR 72.2% vs SoC 43.2%; PFS HR vs SoC 0.37 (95% CI 0.13–1.02; p=0.048); 12-mo PFS 61.9% vs 30.1%.
Clinical relevance: Supports the planned Phase 3.
Source: ASCO Abstract 3510
Indication: 1L mCRC (triplet vs doublet)
Key finding: Biomarker(+) triplet+bevacizumab: 3-yr PFS 17% vs 7% (HR 0.51; p<0.001), OS 43% vs 22% (HR 0.51; p<0.001); biomarker(−) no significant difference.
Clinical relevance: A histology-based predictive biomarker (Simon Level of Evidence IB).
Source: ASCO Abstract 3513
Indication: KRAS G12C-mutant chemorefractory mCRC
Key finding: ≥80% VAF clearance 77.3% (soto 960 + pani), 65.9% (240 mg), 15% (IC); complete VAF clearance 45.5%/31.8%/5.0%; ctDNA clearance prognostic for PFS and OS independent of arm.
Clinical relevance: Supports ctDNA as an early response biomarker.
Source: ASCO Abstract 3511
Indication: MSI-H metastatic CRC on 1L ICI
Key finding: Pre-ICI ctDNA-positive 71.7%; 81% achieved anytime clearance; ctDNA-positive at any time after ICI start associated with HR 8.0 for OS (p<0.0001); first post-ICI ctDNA-positive HR 4.9 for OS.
Clinical relevance: ctDNA correlates with treatment durability and OS.
Source: ASCO Abstract 3516
Indication: RAS wild-type left-sided 1L mCRC
Key finding: SEQ1 vs SEQ2 36-mo PFSR 28.57% vs 22.36% (p=0.224); 1L ORR 80.95% vs 64.25% (p<0.01); PFS1 14.09 vs 12.39 mo (p=0.03); 2L ORR (FOLFIRI+panitumumab) 40.43% vs 27.27% (p=0.03).
Clinical relevance: The primary endpoint was negative, but SEQ1 was superior in early-line metrics.
Source: ASCO Abstract 3512
Indication: Colorectal cancer peritoneal metastases
Key finding: 14 evaluable; ORR 57.1%, DCR 100%, max tumor shrinkage 85.6%; median PFS 4.7 mo; CRS Gr1/2 in 93.3%; 1 DLT (Gr 4 pneumonia).
Clinical relevance: Encouraging activity at ~1/10 conventional CAR-T dose via intraperitoneal delivery.
Source: ASCO Abstract 3514
Indication: pMMR/MSS locally advanced rectal cancer (mRCAT-III) · previously treated BRAF V600E mCRC (LBA3509)
Key finding: Chemoradiotherapy study (mRCAT-III) and tunlametinib + vemurafenib (LBA3509); full text was not available in the source for either.
Clinical relevance: Unclear; must be verified against the full texts.
Source: ASCO Abstract LBA3515 / LBA3509
Indication: Advanced solid tumors (SCLC, ESCC emphasized)
Key finding: RP2D 12 mg/kg; overall ORR 54.5% (30/55); SCLC ORR 71.4%, DCR 100%; ESCC ORR 55.6%, DCR 88.9%; G≥3 TRAE 16.5%; pneumonitis 2.1% (both Gr 1).
Clinical relevance: Notable activity in heavily pretreated SCLC and ESCC.
Source: ASCO Abstract 3011
Indication: EGFR-mutant NSCLC (C797S ± T790M)
Key finding: 72 patients (20–160 mg total daily); bilirubin elevation 36% (UGT1A1-related); in 17 C797S-evaluable patients PRs in 10 (59%); ORR 50% with T790M, 66% without; 7/9 baseline plasma C797S had >99% VAF reduction; no pneumonitis.
Clinical relevance: First TKI monotherapy with clinical activity against C797S ± T790M.
Source: ASCO Abstract 3014
Indication: Advanced solid tumors (OC, TNBC, HR+/HER2− BC)
Key finding: 123 patients; cORR 28.1%; ovarian 34.5%, TNBC 31.3%, HR+/HER2− BC 17.9%; 8 DLTs across dose levels; G≥3 TRAE 30.1%.
Clinical relevance: Tolerable; activity in ovarian and TNBC; expansion ongoing.
Source: ASCO Abstract 3013
Indication: Advanced solid tumors (predominantly HCC)
Key finding: Confirmed ORR 20.3% (12/59); above the predicted target-efficacious dose cORR 28.9% (11/38); G≥3 TR-TEAE in 5 patients; 1 DLT (ALT increase).
Clinical relevance: Durable responses including post-PD-(L)1.
Source: ASCO Abstract 3016
Indication: 1L extensive-stage SCLC (SSTR+)
Key finding: No DLTs; RP2D 7.4 GBq; confirmed best overall response 82.8%; 6-mo PFS 36.1%; 2 AE deaths (not treatment-related).
Clinical relevance: Phase 2 proceeding at 7.4 GBq.
Source: ASCO Abstract 3010
Indication: Advanced metastatic solid tumors with αvβ3 expression
Key finding: ORR 23% (3/13), DCR 92%; median PFS 7.3 mo, OS 18.5 mo; G3/4 TRAE 20%, mainly hematologic.
Clinical relevance: Justifies further randomized investigation.
Source: ASCO Abstract 3009
Indication: Solid tumors with pathogenic ATM mutations
Key finding: 4 Gy × 2 (60% dose reduction) achieved 6-mo local control in 10/12 (83.3%) vs historical 82% for 4 Gy × 5; no grade ≥2 toxicities; biallelic ATM loss in top responders.
Clinical relevance: Feasibility of genomically-guided RT de-escalation.
Source: ASCO Abstract 3015
Indication: Multi-cancer risk prediction
Key finding: AUROC range 0.64–0.80; lung 0.79 (comparable to XGBoost 0.82, logistic regression 0.73, KNN 0.58).
Clinical relevance: A scalable clinical-decision-support tool for risk stratification.
Source: ASCO Abstract 10501
Indication: Cross-cutting (ADC / radioligand / bispecific)
Key finding: Across these early-phase programs, toxicities were largely on-target/manageable — e.g., low-grade pneumonitis for the B7-H3 ADC, mainly hematologic G3/4 for the αvβ3 radioligand, and UGT1A1-related bilirubin elevation for the C797S TKI.
Clinical relevance: A maturing tolerability picture for novel targeted modalities.
Source: ASCO Abstracts 3009–3016
Indication: Metastatic prostate cancer
Key finding: BRCA2-mutant mHSPC shorter OS vs WT (63 vs 76 mo; HR 1.2, p=0.02); ADT+ARPi superior time-on-treatment vs ADT+docetaxel (55 vs 15 mo; HR 3.5, p<0.001); RAD51-BD PVs longer olaparib ToT (20.0 vs 7.0 mo, p=0.01); frameshift deletions shorter OS (15.9 vs 26.0 mo, p=0.04).
Clinical relevance: Refined BRCA2 risk stratification and PARP-inhibitor selection.
Source: ASCO Abstract 10503
Indication: Prostate cancer in men of African ancestry
Key finding: HR 3.38 per 'T' allele (95% CI 2.31–4.95; p=3.92×10⁻¹⁰); ATM rare pathogenic variant HR 7.54 (95% CI 1.84–30.90; p=5.03×10⁻³).
Clinical relevance: Supports inclusion in prostate-cancer genetic panels.
Source: ASCO Abstract 10504
Indication: Germline pathogenic-variant-driven prostate cancer screening
Key finding: csPCa detected in 21/119 biopsies (18%); 2/3 csPCa at PSA <4 ng/mL; PI-RADS 4–5 OR 12.2 (95% CI 3.3–45.4); 11 GG1 elected active surveillance with 1 upgrade.
Clinical relevance: Age-specific PSA + MRI is feasible in pathogenic-variant carriers.
Source: ASCO Abstract 10505
Indication: Prevention; AML/ALL in high-risk adults
Key finding: AML HR 0.37 (95% CI 0.26–0.53; p<0.001); ALL HR 0.50 (95% CI 0.33–0.75; p=0.001); no significant reduction for CML/CLL.
Clinical relevance: A hypothesis-generating pharmacologic-prevention signal.
Source: ASCO Abstract 10507
Indication: Type 2 diabetes, multiple cancers
Key finding: vs metformin: lung HR 0.086 (0.020–0.373; p<0.001), pancreatic HR 0.124 (p=0.022), breast HR 0.462 (p=0.009); vs insulin lower risk across multiple cancers; consistently lower all-cause mortality.
Clinical relevance: Hypothesis-generating; warrants prospective validation.
Source: ASCO Abstract 10508
Indication: Women with BMI > 25
Key finding: Matched OR 0.746 (95% CI 0.632–0.880; p<0.0005); unmatched OR 0.630.
Clinical relevance: Hypothesis-generating; prospective trials needed.
Source: ASCO Abstract 10506
Indication: Multi-cancer (esophageal, lung)
Key finding: Any cancer HR 1.22 (95% CI 1.18–1.27); lung adenocarcinoma HR 1.79; esophageal SCC HR 2.28; multi-hit CHIP esophageal adenocarcinoma HR 4.07.
Clinical relevance: Hypothesis-generating for solid-tumor risk stratification.
Source: ASCO Abstract 10502
Indication: Early-onset cancer (multi)
Key finding: Per SD allostatic load: All of Us OR 1.18 (1.12–1.24); UK Biobank OR 1.11 (1.04–1.18); allostatic load mediated 8.7–15.4% of exposome-related early-onset-cancer risk.
Clinical relevance: Mechanistic insight into a potentially modifiable target.
Source: ASCO Abstract 10500
Indication: Solid tumors with pathogenic ATM (prevention of RT toxicity)
Key finding: See ADC/Targeted section — 4 Gy × 2 achieved 6-mo local control in 83.3% with no grade ≥2 toxicities, informing genomically-guided dose reduction.
Clinical relevance: Links germline/somatic ATM status to safe RT de-escalation.
Source: ASCO Abstract 3015
This report was generated automatically and is not medical advice. Clinical decisions must be verified against official abstract/presentation full texts and current guidelines.
OncoHub.ai · ASCO 2026 Gündem
Bu içerik editoryaldir. Tıbbi tavsiye değildir. Klinik karar hekime aittir.
oncohub.ai →